115 results about "Treated cell" patented technology

The invention provides an improved cell instance segmentation method and system based on YOLOv11, and the method comprises the steps: 1, constructing an improved YOLOv11 network, extracting the multi-scale features of an image, and generating feature maps of different scales; 2, introducing a multi-scale channel attention module into the backbone network, and introducing a new attention module into the multi-scale channel attention module to iteratively optimize initial fusion; step 3, integrating hierarchical feature maps generated by the encoder; 4, adding a scale sequence feature fusion module in the neck network, adding a triple feature encoder module, and fusing feature maps of different scales; step 5, adding a channel and position attention mechanism module in the neck network; and step 6, outputting a final segmentation result. The method is specially designed to be used for cell instance segmentation, and the accuracy and speed of processing cell images are improved by combining space and scale features.

The present disclosure provides systems and methods for processing cells. The systems of the present disclosure may include a compartment, a three-dimensional (3D) matrix, a fluid flow path, an analysis unit, a preservation unit, or any combination thereof. The methods of the present disclosure may process cells via, for example, expansion, culturing, gene delivery, activation, or any combination thereof. The systems and methods described herein may be useful for producing cell products including, for example, cell therapy products.

The invention provides a method and a system for processing a cell image based on a DistSegNet model. The method for detecting the cells based on the DistSegNet model image processing technology comprises the following steps: preprocessing a collected cell image; performing cell segmentation on the cell image based on a DistSegNet model image processing technology to generate a cell nucleus region; based on the segmented cell nucleus region, generating a background region, a foreground region and an edge region by adopting morphological operation; calculating the shortest Euclidean distance from each background region pixel to the nearest foreground region pixel, and segmenting the cell image by using a watershed algorithm; performing result optimization on the segmentation map corresponding to each cell instance label to obtain a filtered segmentation label map; and extracting the outer contour of the intra-nucleus region and the outer contour of the surrounding region of each cell from the segmentation mark graph, and storing the outer contours to a corresponding result file. According to the invention, the accuracy and accuracy of a WSI-level cell detection result can be improved.

The invention provides a method and a system for processing a cell image based on a DistSeg model. The method for detecting the cells based on the DistSeg model image processing technology comprises the following steps: preprocessing a collected cell image; segmenting the cell image based on a DistSeg model image processing technology to generate a cell nucleus region; based on the segmented cell nucleus region, generating a background region, a foreground region and an edge region by adopting morphological operation; calculating the shortest Euclidean distance from each background region pixel to the nearest foreground region pixel, and segmenting the cell image by using a watershed algorithm; performing result optimization on the segmentation map corresponding to each cell instance label to obtain a filtered segmentation label map; and extracting the outer contour of the intra-nucleus region and the outer contour of the surrounding region of each cell from the segmentation mark graph, and storing the outer contours to a corresponding result file. According to the invention, the accuracy and accuracy of a WSI-level cell detection result can be improved.

The present invention relates to a microfluidic device (1) for forming a cell aggregate comprising at least one first cell (C1) and one second cell (C2), and for individually processing selected cells of the cell aggregate: - Microfluidic channel (10); - At least one main inlet (11) for fluids containing a first cell, a second cell, and a third cell, respectively, located in the first portion (101) of the microfluidic channel; - An outlet (12) located in the second portion (102) of the microfluidic channel for controlling the flow rate of fluid within the microfluidic channel; - A first auxiliary inlet (131) for at least one first auxiliary fluid, located in the first portion (101) of the microfluidic channel upstream or downstream of the main inlet (11); - At least one cell trapping section (14) positioned between the first and second parts within the microfluidic channel; - At least one first valve to control the flow rate of the first auxiliary fluid, causing the fluid containing the first cells and the second cells to flow at a predetermined height within the microfluidic channel, thereby guiding the first cells and the second cells to the first and second capture units, respectively. Equipped with, The microfluidic device relates to a microfluidic device in which each cell capture section (14) comprises at least one first capture section (141) and one second capture section (142), each first and second capture section being sized to accommodate a first or second cell, the first and second capture sections being adjacent to each other in a direction perpendicular to the bottom (100) of the microfluidic channel, and forming a cell aggregate containing the captured first and second cells, each cell being at a different height relative to the bottom of the microfluidic channel.

The invention provides a method for producing cell culture meat through 3D scaffold-free co-culture of pseudosciaena crocea stem cell spheres, and belongs to the technical field of preparation of cell culture meat. A method for producing cell culture meat by 3D scaffold-free co-culture of pseudosciaena crocea stem cell spheres comprises the following steps: mixing and inoculating pseudosciaena crocea myoblasts and pseudosciaena crocea precursor adipocytes into a cell culture plate subjected to anti-adhesion treatment for proliferation culture, spontaneously gathering to form cell spheres, and carrying out differentiation culture to obtain the cell culture meat. According to the co-culture mode provided by the invention, high-efficiency myogenic differentiation and adipogenic differentiation of myoblasts and precursor adipocytes of the large yellow croakers can be realized through proliferation culture and differentiation culture, and an in-vivo microenvironment can be effectively simulated, so that cultured meat similar to a traditional meat product in texture and flavor is produced.

The present invention relates to a hybrid exosome formed by the fusion of a human cell-derived exosome and an artificial exosome. When an active ingredient labeled with a fluorescent material was attached or encapsulated in the hybrid exosome of the present invention and applied to cells, the active ingredient was observed in the cells. In addition, when the exosome was applied to skin tissue, fluorescence expression could also be observed in the dermal layer. Therefore, the hybrid exosome according to the present invention can be used as a novel drug delivery system.

The invention discloses a gray clustering characteristic distribution-based cell nucleoplasm segmentation method, which comprises the following steps of: 1) constructing a self-supervised network, and solving a cell intensity distribution diagram of a cell image; 2) determining cell candidate regions in the intensity maps of the cell distribution, the staining intensities of the intensity maps of the cell distribution are different, but the deepest part in the image must belong to a cell nucleoplasm region, so that the candidate regions of the cell nucleoplasm are solved by adopting an iterative search mode; and 3) carrying out accurate segmentation on the obtained candidate cell region to obtain a segmentation result of the cell nucleoplasm, and finally, correspondingly drawing a minimum circumscribed contour of the cell nucleoplasm in the original color map. The invention belongs to the technical field of image processing and biomedicine, and solves the problems that in the prior art, when a cell image is processed, the extraction part is inaccurate, impurities are easy to mix, and the detection precision is influenced.

The invention discloses a cell image segmentation and function prediction method and device and computer equipment. The method comprises the steps of obtaining a to-be-processed cell image; inputting the to-be-processed cell image into the segmentation model for segmentation to obtain physical morphological features; inputting the physical morphological characteristics into a function prediction model to predict relevant parameters of the cell biological characteristics and relevant indexes of a set type of curative effect so as to obtain the parameters of the cell biological characteristics and the relevant indexes; and outputting physical morphological characteristics, cell biological characteristic parameters and related indexes. By implementing the method provided by the invention, the undyed bright field cell image can be effectively processed, the cell morphology and function are associated, the method is specially used for segmenting the mesenchymal stem cells, and the problem of instance segmentation under the condition of cell overlapping is solved.

The invention discloses an application of a hypoxia pretreated extracellular vesicle / miR-27b-3p in the treatment of ischemic stroke. The research proves that both the neuron-derived EV and H-EV can promote in-vivo and in-vitro MCAO repair. The two vesicles secreted by neuronal cells can significantly influence phenotypic change and apoptosis of astrocytes, wherein the effect of H-EV is more obvious than that of EV. Besides, the research result shows that H-EV secreted by neurons can regulate a PI3K / AKT signal channel by transmitting miR-27b-3p, so that astrocytes are promoted to be converted from the A1 phenotype to the A2 phenotype. The research of the invention provides a new therapeutic target and strategy for treating ischemic stroke.

To detect an inclination of a cartridge, the cartridge being configured to internally perform processing on a cell.SOLUTION: A sample processing apparatus according to the present embodiment includes an apparatus body. In the apparatus body, a cartridge for internally performing processing on a cell is installed, and the apparatus body controls liquid feeding in the cartridge and / or adjusts an environment in the cartridge. The apparatus body includes a detector configured to detect an inclination of the cartridge with respect to a horizontal plane and / or the apparatus body.SELECTED DRAWING: Figure 5

The present invention discloses an in vitro preparation method of human mesenchymal stem cells. The method comprises the following steps: using MSC culture medium supplemented with chemical small molecules to induce iPSC-derived MSCs; after the iPSC cell confluence reaches 40%, the culture medium containing chemical small molecules is replaced; after 8-10 days of induction, the cells are collected and passaged; and the cells are cultured to the P1 generation, showing uniform fibroblast-like, spindle-shaped or fusiform cells. The prepared hiPSC-MSCs meet the relevant phenotypes of mesenchymal stem cells, wherein the positive rates of CD73, CD90 and CD105 are higher than 95%, and the cells have immunomodulatory activity.

The present invention relates to a method for performing a biological process on a liquid immune cell or an initial cell culture to obtain a treated cell culture, where the treated cell culture is intended for autologous or allogeneic cell therapy, where the biological process is performed on an integrated biological treatment system (1), wherein the biological process comprises a series of treatment steps wherein the treatment steps each comprise at least one operation wherein the biological process system (1) comprises a base structure (3) and a preconfigurable cartridge (4) wherein the biological process system (1) performs the operation of the biological process via interaction of the base structure (3) with the cartridge (4), wherein the cartridge (4) and the base structure (3) comprise a matching standardized interface (6) for interaction of the base structure (3) with a corresponding cartridge (4), wherein the biological process system (1) performs at least two operations of the biological process inside at least two differently preconfigured cartridges (4) by interaction of the base structure (3) with the cartridges (4) via the same base structure interface (7) and / or the same base structure interface (7) and a mating cartridge interface (8).

The present invention provides: a single-strand form polynucleotide for editing that is capable of modifying a target site in double-strand genomic DNA and that includes, as a structural unit, a nucleotide analog with a high affinity for DNA; a genome editing kit that includes said polynucleotide for editing; a genome editing kit that includes said polynucleotide for editing and a polynucleotide for promoting editing or an expression vector thereof; a method for modifying a target site in double-strand genomic DNA of a cell or a non-human organism, the method comprising a step for using the genome editing kit to treat a cell or an organism; 10 and a method for producing a cell or an organism in which a target site in double-strand genomic DNA is modified, the method comprising said step.

In one aspect, a method of treating an NK cell to induce a gene edit. The method may include contacting an NK cell with a transfection composition including poly-L-glutamic acid (y- PGA), a single-stranded oligo deoxynucleotide (ssODN) enhancer, or a combination thereof; contacting the NK cell with an editing composition including: a DNA-PK inhibitor, and an HD AC inhibitor; electroporating the NK cell; and contacting the NK cell with a recovery composition including DNase I. In another aspect, a method of preparing an engineered NK cell comprising a fluorescent reporter at an endogenous locus. In another aspect, a method of treating an NK cell to introduce an exogenous nucleic acid.

To reduce complication in incorporating a reagent into a cartridge for cell treatment.SOLUTION: A cartridge according to an embodiment is a cartridge for performing processing of cells therein, and includes a flow path through which a reagent used for the processing flows, a connection portion for connecting a reagent container containing the reagent to the flow path, and an opening / closing portion for connecting the reagent container to the connection portion and installing the reagent container in the cartridge.SELECTED DRAWING: Figure 4

The application discloses an animal cell adaptive tracking method and system based on deep learning, and belongs to the technical field of cell image analysis; a YOLOv10 deep learning model is combined with a Btrack adaptive tracking algorithm, animal cell samples are first dyed and microimage collection is carried out, a cell detection model is trained after image preprocessing, data labeling and augmentation, the model is converted into an ONNX format to realize efficient inference; then, Kalman filtering prediction and three-round Hungarian algorithm matching are carried out to complete cell adaptive tracking, the problems of cell occlusion, division, overlap and loss of tracking can be effectively handled, and stable and continuous cell motion trajectories are generated; the application can be deployed without GPU, has strong generalization ability, high detection and tracking precision, is suitable for scenes such as microecological research, clinical sample testing, drug effect evaluation and cell behavior analysis, and can significantly improve the automation level and stability of animal cell detection, counting and dynamic tracking.

Disclosed are methods for selecting, expanding,and / or enriching cells that are resistant to an immunosuppressive agent (e.g., MTX), and the method comprising treating the cells with the immunosuppressive agent and human platelet lysate (HPL). In some embodiments, the cells (e.g., CAR-T cells) can be used for cell therapy.

The present disclosure pertains to methods for handling cells and / or cell clusters without the use of centrifugation. In one aspect, described is a method of separating a liquid from a composition comprising the liquid and cell clusters. Therein, the liquid of the composition is passed through a filter disposed within a pipette so as to separate the liquid from the cell clusters.

Plant cell fate and development is altered by treating cells with cellular reprogramming factors. Embryogenesis inducing embryogenesis factor genes and / or morphogenic developmental genes are used as cellular reprogramming factors, specifically comprising polypeptides or polynucleotides encoding gene products for generating doubled haploids or haploid plants from gametes. Maize microspores treated by contacting the isolated cells with an exogenous purified, recombinant embryogenesis inducing embryogenesis factor gene products and / or morphogenic developmental gene polypeptide results in embryogenesis. The gametes of a maize plant develop into embryoids when transformed with a genetic construct including regulatory elements and structural genes capable of acting in a cascading fashion to alter cellular fate of plant cells. Embryogenesis factor proteins and / or developmental morphogenic proteins expressed from a genetic construct are used for ex situ treatment methods and for in planta cellular reprogramming.

The invention belongs to the technical field of algae physiology, and particularly discloses a method for efficiently extracting microalgae chlorophyll, which comprises the following steps: a, taking an algae liquid sample, centrifuging, discarding supernatant, and adding 90% ethanol solution for resuspension; b, adding quartz sand into the resuspension, carrying out cell homogenization treatment under the condition of 60 Hz, repeating the cell homogenization treatment for 4 times, 45 seconds each time, and 5 seconds each time; and c, heating the sample in a constant-temperature water bath at 60 DEG C for 7 minutes, centrifuging, and collecting supernate. By optimizing the ethanol concentration, the cell homogenization time, the cell homogenization material and the hot bath time, the cell homogenization technology of combining an ethanol method with quartz sand broken algae cells is improved, the chlorophyll extraction efficiency is effectively improved, the stability is good, and large-scale application is easy. Compared with an acetone method, an ethanol method and an ethanol-steel ball method, the microalgae chlorophyll extraction method provided by the invention has obvious advantages.

Provided is a cell processing method including: preparing a cell suspension containing a cell to be processed and a target substance; and introducing the target substance into the cell to be processed by allowing a shear force to act on the cell to be processed, wherein the cell to be processed is a cell, which is selected from a cell group including cells in a proliferation process, and which has a cell diameter larger than a mode in a cell diameter distribution of the cell group.

The invention belongs to the cross technical field of cell engineering, nano-drugs and biological manufacturing, and particularly discloses a drug-loaded vesicle based on denucleated cells as well as a preparation method and application of the drug-loaded vesicle. According to the invention, a cell suspension and a cytoskeleton relaxant are co-incubated to relax an actin skeleton and weaken nucleoplasm connection; then loading the treated cell suspension on a multi-layer discontinuous density gradient centrifugal medium, realizing physical separation of cell nucleuses and cytoplasm through high-speed centrifugation according to buoyancy density difference, and collecting components of a specific interface to obtain high-purity denucleated cells with a complete membrane structure; then co-incubating the denucleated cells and ROS response type lipidosome (co-carrying therapeutic siRNA and a sound-sensitive agent Ce6) prepared in advance, so that the lipidosome is wrapped or anchored by a denucleated cell membrane; finally, the composite system is subjected to extrusion treatment through a microporous membrane, the drug-loaded vesicles uniform in particle size and stable in structure are obtained, and the drug-loaded vesicles are suitable for various application scenes such as anti-tumor treatment and RNA vaccine delivery.

To provide a container that allows cells to be easily handled in a sterile manner. [Solution] A container 300 used for liquid phase exchange of a cell suspension, comprising: a container body 310 having a pair of ends 314a, 314b located at both ends in a first direction, and a peripheral portion 312 extending along the first direction and forming a closed space by connecting the pair of ends 314a, 314b; and two openable and closable openings 320, 330 provided on the container body 310, wherein the first opening 330 is arranged on the first end 314a side of the peripheral portion 312, and the second opening 320 is arranged on the second end 314b, and cells are deposited at a position 340 on the peripheral portion 312 facing the first opening 330.

The application of BAHCC1 gene in preparing acute myeloid leukemia drugs belongs to the technical field of biological medicine. In order to solve the problems of treating acute myeloid leukemia and reducing its recurrence and drug resistance, the present application significantly inhibits the proliferation and clonogenic ability of acute myeloid leukemia by knocking down BAHCC1, and significantly induces the apoptosis of acute myeloid leukemia and promotes cell differentiation. The three-dimensional spatial structure of BAHCC1 protein is predicted by using AlphaFold software, small molecule compounds targeting BAHCC1 are screened in the three-dimensional spatial structure domain of BAHCC1 protein, and AML cells are treated by using the small molecule compounds targeting BAHCC1. The small molecule compounds targeting BAHCC1 are screened by molecular docking and cell experiments, including 8OK. The small molecule compounds targeting BAHCC1 are combined with cytarabine AraC, daunorubicin DNR or doxorubicin DOX.

The present invention relates to the field of stem cell technology and specifically discloses an application of mesenchymal stem cells (MSCs) for the treatment of lower extremity venous ischemia. This application involves pre-treating human mesenchymal stem cells (hMSCs) with the SDF1-FGF2 fusion protein. This pre-treatment significantly enhances the cell viability, blood flow recovery, and anti-inflammatory effects of hMSCs in a lower extremity venous ischemia model. When hMSCs pre-treated with SDF1-FGF2 were injected into mice modeling venous ischemia, they demonstrated superior effects compared to untreated cells in improving blood perfusion, reducing inflammatory responses, and restoring motor function. This method provides a highly effective stem cell therapy strategy for vascular diseases such as lower extremity venous ischemia.

The invention discloses application of a BAHCC1 gene in preparation of acute myelogenous leukemia drugs, and belongs to the technical field of biological medicines. In order to treat the acute myelogenous leukemia and reduce the recurrence and drug resistance of the acute myelogenous leukemia, the knock-down BAHCC1 disclosed by the invention has the advantages that the proliferation and clone formation capabilities of the acute myelogenous leukemia are remarkably inhibited, the apoptosis of the acute myelogenous leukemia is remarkably induced, and the cell differentiation is promoted. AlphaFold software is used for predicting the three-dimensional space structure of the BAHCC1 protein, a small molecule compound targeting BAHCC1 is screened in the three-dimensional space structure domain of the BAHCC1 protein, and the small molecule compound targeting BAHCC1 is used for treating AML cells. A small molecule compound, including 8OK, targeting BAHCC1 is screened through molecular docking and cell experiments. The small molecular compound targeting BAHCC1 is combined with cytarabine arabinoside AraC, daunorubicin DNR or doxorubicin DOX for use.

An example microscopy system includes a stage for receiving a sample with cells, and an objective lens, a light source, and a detection sensor all in optical communication with the stage. The microscopy system also includes a controller communicatively coupled to the detection sensor and the light source, and the controller includes a processor and a memory with a readable set of instructions, which when executed by the processor, cause the processor to receive an image of the cells, apply a first machine learning algorithm to the image that is arranged to output a corresponding mask image of a nucleus of a cell, apply a second algorithm to the corresponding mask image that is arranged to identify contiguous pixels within the nucleus having a pixel value above a configurable threshold and determine a number of lobes of the nucleus based on a number of groups of the contiguous pixels.

The application discloses active peptides with antioxidant and alcoholic liver injury protection efficacy and application thereof. The application takes walnut protein enzymatic hydrolysate as raw material, and two novel high-antioxidant activity peptide segments HGEPGQQQR and VAPFPEVFGK are screened. The two active peptides show good antioxidant activity at a cell level, and the EC 50 values thereof are 0.0120 mg / mL and 0.0068 mg / mL respectively, which are better than 0.0122 mg / mL of a positive control glutathione. In an ethanol injury model, the two antioxidant peptides can increase the survival rate of cells treated by ethanol from 47.35% to 62.69% and 57.05% respectively. The results show that the walnut protein-derived antioxidant peptides HGEPGQQQR and VAPFPEVFGK can be developed and used as a potential antioxidant and liver protection active ingredient.

A method of obtaining cell derived vesicles comprising an active wild-type p53 is disclosed. The method comprising: (i) isolating cell derived vesicles from a biological sample comprising cells; and (ii) treating the cell derived vesicles with a DNA damaging agent, or the method comprising: (i) treating cells with a DNA damaging agent; and (ii) isolating cell derived vesicles from a biological sample comprising the cells. A proteinaceous preparation comprising cell derived vesicles and a pharmaceutical composition comprising the proteinaceous preparation are also disclosed. Methods of treating a disease, disorder or condition associated with a mutant or a nonfunctional p53 protein and methods of inducing apoptosis of a target cell comprising a mutant or a nonfunctional p53 protein are also disclosed.